CV Therapeutics Announces Ranexa(TM) Abstracts to Be Presented
2003-08-20 16:30 (New York)
At European Society of Cardiology Congress
PALO ALTO, Calif., Aug. 20 /PRNewswire-FirstCall/ -- CV Therapeutics, Inc.
(Nasdaq: CVTX) today announced that two abstracts, featuring data from
clinical studies with Ranexa(TM) (ranolazine), have been accepted for
presentation at the European Society of Cardiology (ESC) Congress 2003, taking
place in Vienna, Austria from August 30 through September 3, 2003. The
accepted abstracts are:
-- Ranolazine Decreases Hemoglobin A1c (HbA1c) in Angina Patients with
Diabetes: Carbohydrate and Lipid Parameters in MARISA and CARISA
-- B. Chaitman, S. Skettino, M. Jerling, J. Skopal, G. Chumakova,
J. Kuch, W. Wang, A. Wolff. Sunday, August 31, 2003 from 12:00 to
12:15 p.m. GMT+0200, Ankara (Blue Zone), Messezentrum Wien. Session
title: New Clinical Therapeutic Approaches in Myocardial Ischemia,
abstract #189.
-- Rebound Worsening in Exercise Performance Was Not Observed After Abrupt
Ranolazine Withdrawal in Patients with Chronic Angina in CARISA
-- J.O. Parker, B. Chaitman, J. Skopal, G. Chumakova, J. Kuch, W. Wang,
S. Skettino, A. Wolff. Sunday, August 31, 2003 from 11:45 a.m. to
12:00 p.m. GMT+0200, Ankara (Blue Zone), Messezentrum Wien. Session
title: New Clinical Therapeutic Approaches in Myocardial Ischemia,
abstract #188.
Additional information regarding the European Society of Cardiology
Congress 2003 can be accessed at escardio.org.
None of CV Therapeutics' products have been approved for marketing by the
FDA or regulatory authorities outside the United States. Any products of the
company discussed here are currently under investigation in clinical trials
subject to United States Investigational New Drug applications, and as
applicable, appropriate clinical trial applications to regulatory authorities
outside the United States. CV Therapeutics' products have not been determined
to be safe or effective in humans for any uses.
CV Therapeutics, Inc., headquartered in Palo Alto, California, is a
biopharmaceutical company focused on applying molecular cardiology to the
discovery, development and commercialization of novel, small molecule drugs
for the treatment of cardiovascular diseases. CV Therapeutics currently has
four compounds in clinical trials. If approved by the FDA, Ranexa(TM) would
represent the first new class of anti-anginal therapy in more than 20 years.
Tecadenoson, an A1-adenosine receptor agonist, is being developed for the
potential reduction of rapid heart rate during atrial arrhythmias. CVT-3146,
a selective A2A-adenosine receptor agonist, is being developed for potential
use as a pharmacologic stress agent in cardiac perfusion imaging studies.
Adentri(TM), an A1-adenosine receptor antagonist for the potential treatment
of acute and chronic congestive heart failure, is licensed to Biogen, Inc.
For more information, please visit CV Therapeutics' website at
cvt.com. |
